June 2026 Research Update

Across this month's papers, treatment research spanned early-stage human studies and several lab-based approaches. In people, results were exploratory and mainly focused on safety and signals of change in heart markers or movement scores, with uncertainty because studies were small and did not include a placebo comparison. In the lab, multiple projects targeted cell energy stress, oxidative stress, and mitochondrial function, but these results have not yet shown benefit in patients. [1] [2] [3] [4] [5]

One open-label, nonrandomized dose-escalation trial tested intravenous AAVrh.10hFXN gene therapy in 17 adults with Friedreich ataxia related cardiomyopathy followed for about 20 months. Serious side effects occurred in 4 people and resolved, including one case described as possibly vector-related myocarditis about 12 months after therapy and others possibly related to prednisone used for immune suppression. Exploratory heart measures showed increased frataxin protein in heart biopsy samples, lower left ventricular mass index in 9 people and stability in 8, and lower high-sensitivity troponin I in most participants (excluding the myocarditis case). [1]

Another human study tested 10 days of anodal cerebellar transcranial direct current stimulation (a noninvasive brain stimulation technique) in 19 people with Friedreich ataxia and 17 healthy controls. Measures of sensorimotor cortex activity and proprioceptive processing did not change with stimulation in either group, but the Friedreich ataxia group had a significant improvement on the Scale for the Assessment and Rating of Ataxia (SARA) after the treatment period. Because the study was not sham-controlled, it cannot show whether the improvement was due to stimulation or other factors. [2]

Two preclinical studies focused on reducing mitochondrial stress and improving cell maintenance pathways. In a mouse model and frataxin-deficient cells, UA-36 (a water-soluble derivative of urolithin A) increased frataxin protein, appeared to restart autophagic flux (a cell cleanup process), improved measures related to mitochondrial function and redox balance, improved motor performance tests, and reduced tissue signs such as iron deposition in the cerebellum and heart and muscle changes in the model. In patient-derived cell models (sensory neurons and heart muscle cells from the same individuals), a chemical probe called MR3 that binds Miro1 reduced mitochondrial reactive oxygen species and restored membrane potential in sensory neurons, and the authors identified additional Miro1-binding compounds through virtual screening with reported neuroprotective capacity in their experimental system. [3] [4]

A systematic review and meta-analysis of fruit fly Friedreich ataxia models summarized many genetic modifier experiments and found that interventions affecting iron handling, mitochondrial dynamics, and oxidative stress often improved disease-related fly outcomes, with ferritin overexpression, Miro inhibition, and catalase overexpression highlighted among top modifiers. The review also reported high differences between studies and called for more standardized methods and reporting to make results easier to reproduce and compare across labs. [5]

For patients and caregivers, the main near-term relevance is that some approaches are now being tested in people, but the evidence is still early and uncertain because the studies were small and lacked placebo comparisons. The gene therapy study focused on heart involvement and reported both serious side effects and signals of improvement in heart-related markers, while the brain stimulation study reported improved ataxia rating scores without clear changes on brain activity measures. The lab studies help identify possible biological targets (such as autophagy and mitochondrial stress pathways, including Miro1) that could inform future treatments, but these results are not yet proof that the same benefits will occur in humans. [1] [2] [3] [4] [5]

Across this group of studies, the picture that emerges is twofold: (1) frataxin deficiency can directly disrupt how heart muscle cells handle energy and contraction in lab models, and (2) in a small real-world group, a commonly used Friedreich ataxia medicine was linked to a more artery-clogging blood fat pattern over time. Both lines of evidence point to potentially important heart-related risks, but they answer different questions and come from early-stage, limited-size studies. [6] [7]

In patient-derived heart muscle cells grown in the lab, Friedreich ataxia cells showed abnormal beating patterns, including longer contraction and relaxation and faster beating, along with irregular calcium signals. These cells also had signs of mitochondrial stress, including higher mitochondrial reactive oxygen species, more mitochondrial fission, and more cell death, and iron exposure made these problems worse. [6]

The same lab study identified two genes (MEG3 and PCDHGA10) that were consistently misregulated across three Friedreich ataxia cell lines, and lowering their activity reduced disease-related cell death. Lowering PCDHGA10 also reduced the elevated mitochondrial reactive oxygen species, suggesting a possible pathway that links frataxin deficiency to cell injury. [6]

In a retrospective real-world study of 17 adults taking omaveloxolone, blood fat testing over 12 months showed a sustained rise in total cholesterol, LDL cholesterol, and ApoB, while HDL cholesterol and triglycerides stayed about the same. This pattern suggests a shift toward a more atherogenic lipid profile during the observation period, although the study did not test whether this changed actual rates of heart events. [7]

For patients and caregivers, these studies mainly add background about two different kinds of heart-related risk in Friedreich ataxia: disease biology inside heart cells (shown in a lab model) and changes in cholesterol-related blood markers seen during omaveloxolone use (seen in a small real-world group). The lab work helps explain how frataxin deficiency could strain heart cells but does not directly predict an individual person's heart outcomes. The omaveloxolone study suggests that cholesterol markers may change over time in some people, but it cannot prove cause and effect or show how much this matters for long-term heart health.

Across this research, cough strength in Friedreich ataxia varied widely, and reduced cough flow was not rare. Lower cough strength tended to go along with weaker breathing muscles and certain disease features, suggesting cough problems may be part of broader respiratory muscle involvement. [8]

In a cross-sectional study of 51 people with genetically confirmed Friedreich ataxia (47 completed cough testing), 17 people had reduced peak cough flow based on the study's cutoff. Reduced cough flow was linked to younger age, earlier symptom onset, and weaker breathing muscles. [8]

Cough flow rose and fell in step with several breathing measurements, including inspiratory strength (maximal inspiratory pressure), expiratory strength (maximal expiratory pressure), and a standard breathing test measure (forced vital capacity percent predicted). When looking at multiple factors together, inspiratory muscle strength and age at symptom onset were the strongest predictors of cough flow in this dataset. [8]

For patients and caregivers, this study mainly helps explain why coughing can become less effective in Friedreich ataxia: it often tracks with measurable breathing muscle weakness and may be more common in people with earlier-onset disease. It does not show what will happen for any one person over time, because it was a one-time snapshot rather than a long-term follow-up. More research is still needed to learn how cough strength changes as the condition progresses and how well cough measurements predict real-world risks like chest infections. [8]

Across two observational studies, a consistent picture emerged that Friedreich ataxia (FA) is associated with changes in thinking skills, especially certain types of verbal fluency, as well as with adverse life events and differences in emotional and social well-being. Cognitive changes did not seem to be fully explained by speech clarity alone, and the mix of life stresses differed by whether FA began in childhood or adulthood. Both studies were not treatment trials, so they describe patterns rather than how to change outcomes. [9] [10]

In a prospective cohort comparing 101 people with FA to 43 age-matched controls, definite Cerebellar Cognitive Affective Syndrome (CCAS) was more common in FA (47% vs 12%). The most frequent areas of difficulty were phonemic fluency (44%), categoric switching (41%), and semantic fluency (20%), which can show up as trouble generating words or shifting between categories during conversation or tasks. Higher education was linked to higher CCAS scores, while worse day-to-day function was linked to lower CCAS scores, suggesting that cognitive test performance related to both background factors and disability level. [9]

In the same study, speech impairment (dysarthria) did not explain CCAS scores after statistical adjustment, meaning lower scores were not simply a byproduct of speaking less clearly. This supports the idea that some thinking and mood-related changes can be part of FA itself, even when communication is affected. [9]

In a cross-sectional study of 73 people with FA, disease-related life events were the most common type reported, and people with adult-onset FA reported a broader range of events (including positive events). Relationship-related events were more frequent with greater disability, especially in people who were non-ambulant, and this pattern differed by onset group (pediatric-onset participants showed more relationship-related events at the non-ambulant stage). Higher well-being scores were linked to fewer adverse life events reported overall, suggesting that life stress and well-being moved in opposite directions in this dataset. [10]

For patients and caregivers, these studies add context for why FA can feel like more than a movement condition: it may include specific thinking/communication challenges (like word generation and switching between topics) and a substantial load of life transitions that can affect relationships and well-being. The evidence here mainly matters now as a clearer description of what some people experience and how it relates to day-to-day function, rather than as guidance on what to do. What remains uncertain is how these patterns change over time for an individual person, because one study was cross-sectional and neither study tested whether any specific support or intervention changes outcomes. [9] [10]

Across these studies, the main message is that Friedreich ataxia (FRDA) risk and severity can depend on which exact frataxin (FXN) gene change a person has, and that some changes are easier to miss with standard testing. One study focused on people whose results initially suggested only one expanded GAA repeat, but later were found to have an FXN deletion that may help explain a more severe course. Another study traced how certain repeat-length patterns in FXN are distributed across populations and over time, helping explain why FRDA is common in some ancestries and rare in others. [11] [12]

In the FACOMS natural history cohort, people with FRDA who had proximal deletions in FXN (and were initially thought to have only one GAA expansion allele) had more severe disease than people with two expanded alleles. The report noted higher rates of cardiomyopathy (heart muscle disease), diabetes, and optic neuropathy (damage to the nerve that connects the eye to the brain). [11]

The same clinical study also reported that these proximal deletion cases looked similar to people with other severe loss-of-function FXN changes, such as distal deletions or variants expected to eliminate FXN function. The authors highlighted a diagnostic implication: if someone has a severe FRDA-like picture but testing does not show two expanded alleles, additional genetic evaluation for deletions may be important to consider in the diagnostic workup. [11]

A separate population genetics study described FXN "protomutations" that arise from a subset of longer long-normal alleles and fall into two main haplotype-related subclasses. The study concluded these protomutations can act as a reservoir that generates premutations and disease-causing expanded GAA alleles over generations. [12]

In that population study, protomutations were reported to be absent in sub-Saharan Africa, which the authors used to help explain why FRDA is largely absent in that region. The study also reported that Eurasian admixture can introduce protomutation or expanded alleles into African American populations, and ancient DNA analyses suggested these protomutations have circulated in parts of Europe and Western Asia for thousands of years. [12]

For patients and families, these papers mainly add context about why FRDA can look different from person to person and why genetic results can sometimes be more complex than "two expanded repeats." The deletion study is most relevant as background for understanding severe heart involvement, diabetes, or vision-related complications in people whose initial testing did not show two expanded alleles, but it does not by itself predict an individual course. The population genetics work does not change care now, but it helps explain why FRDA risk differs by ancestry and geography; what remains uncertain is how often these specific intermediate repeat states lead to expanded repeats in any one family or community.

Across this group, research focused on improving how Friedreich ataxia and related ataxias are measured over time, especially for clinical trials. Two approaches stood out: using movement sensors with artificial intelligence to better reflect clinical ataxia severity, and using magnetic resonance imaging (MRI) measures chosen to match each specific ataxia type. [13] [14]

In an exploratory validation study in people with Friedreich ataxia, a two-stage artificial intelligence model helped transfer information between two wearable movement-sensor tools, and it aligned more closely with a standard clinical ataxia score than a conventional model. For one tool, the model-to-clinical-score fit rose to R^2 = 0.62 from 0.53, and for the other it rose to R^2 = 0.49 from 0.46. [13]

A separate expert consensus paper reviewed MRI measures that could be used as trial end points in Friedreich ataxia and several spinocerebellar ataxias, and it provided disease-specific recommendations rather than a one-size-fits-all approach. It also highlighted knowledge gaps, meaning some MRI measures still need more evidence before they can be relied on as stand-alone trial outcomes. [14]

This work mainly matters for how researchers measure change in Friedreich ataxia, especially in clinical studies where small changes can be hard to detect. Wearable sensors and MRI-based markers may help make tracking more consistent and sensitive, but the sensor approach here was exploratory and the MRI recommendations still include areas where evidence is limited, so it is not yet clear which measures will become standard across studies. [13] [14]

Two studies looked at disease impact from different angles: population-level outcomes over decades and biological changes that may contribute to coordination problems. Together, they suggest that both broad trends (like mortality patterns) and specific nervous system functions (like body position sensing) are important for understanding and tracking the full burden of hereditary ataxias, including Friedreich ataxia. [15] [16]

In a population-based analysis of US death data from 2000 to 2020 using the hereditary ataxia code (G11), age-adjusted mortality increased over time. Mortality was consistently higher in males, and the largest relative increases were reported among Black individuals and in the West census region; forecasts to 2050 also indicated increasing mortality overall, with more uncertainty within subgroups. [15]

In an exploratory mouse study, turning off frataxin in a set of sensory neurons involved in proprioception (the sense of body position) led to a clear change over time: normal gait early on, then severe locomotor ataxia later. By 8.5 weeks, the mice showed reduced or absent stretch sensitivity in proprioceptive signals, while the muscle spindle structure was mostly preserved and nerve endings showed minor degeneration. [16]

The mortality study adds context about how hereditary ataxia outcomes have changed in the United States and highlights differences across groups, but it is based on how conditions are coded on death certificates and it does not separate Friedreich ataxia from other hereditary ataxias. The mouse study is background science that may help explain why balance and coordination can worsen, but animal results do not always translate directly to people and do not by themselves provide a way to monitor disease in the clinic. [15] [16]

Across countries, specialist ataxia centers were described as providing care that feels more tailored to Friedreich ataxia and better informed, but getting to these centers could require extra travel and coordination. In this survey, overall healthcare spending over a year did not clearly differ between people mainly seen in specialist centers versus non-specialist settings, although experiences varied by country. [17]

In the UK and Italy parts of the survey, total 12-month costs per person were not significantly different when comparing specialist ataxia center care with non-specialist care. This suggests that, at least in these settings and within this sample, specialist-centered care did not automatically mean higher overall yearly costs. [17]

People reported that specialist ataxia centers were valued for staff understanding of the condition and for opportunities to participate in research, and some respondents reported higher satisfaction with specialist care. At the same time, the survey described access barriers such as travel burden and limited awareness or referral pathways, and multidisciplinary team access and care coordination differed across the three countries. [17]

The results should be read with some caution because the sample was small and recruited through patient organizations, which may over-represent people who are more connected to care and research. The German sample also lacked a non-specialist comparison group, which limited between-group comparisons there, and different data collection periods required adjustments. [17]

For patients and caregivers, this research mainly helps explain how access and experience can differ depending on whether care is centered in a specialist ataxia clinic or delivered in general neurology and local services. It suggests that specialist care may feel more knowledgeable and better linked to research without clearly increasing overall yearly healthcare costs in the surveyed UK and Italy groups, but it also highlights practical burdens like travel and uneven multidisciplinary access. What remains uncertain is whether the same cost pattern holds in larger, more representative groups and in healthcare systems not captured in this survey. [17]